Lilly gets another obesity partner in deal with Superluminal worth up to $1.3B

Eli Lilly is linking arms with a machine learning-driven startup for its next bet on obesity R&D. The Indianapolis pharma said it will deliver up to $1.3 billion in a pact with Superluminal Medicines. The ...